Integral Ad Science Reports Q3 2025 Earnings, Exceeds Revenue Guidance, Announces Acquisition by Novacap

IAS
November 04, 2025

Integral Ad Science reported its third‑quarter 2025 financial results on November 4, 2025. Revenue totaled $154.4 million, a 16% year‑over‑year increase from $133.5 million in Q3 2024. Net income was $7.0 million, down from $16.1 million in the prior year, giving a net‑income margin of 4.5%. Adjusted EBITDA reached $55.3 million, representing a 35.8% margin on revenue.

Revenue growth was driven by the optimization segment, which generated $73.7 million (21% YoY), the publisher segment, which produced $23.5 million (21% YoY), and the measurement segment, which delivered $57.1 million (8% YoY). Higher operating costs contributed to the decline in net income relative to the previous year.

IAS exceeded its Q3 revenue guidance of $148–$150 million. Because the company is in the process of being acquired, it will not provide a full‑year outlook for 2025.

IAS entered into a definitive agreement to be acquired by Novacap for $10.30 per share, valuing the transaction at approximately $1.9 billion. The purchase price represents a 22% premium over the closing price on September 23, 2025. Closing is expected in Q4 2025. Termination fees are $52.5 million for IAS and $100 million for Novacap, and existing shareholder Vista will exit its investment.

The acquisition marks IAS’s transition to a private company and is expected to provide resources for AI‑first technology investment and accelerate innovation in digital advertising verification.

In Q2 2025, IAS reported revenue of $149.2 million, net income of $16.4 million, and adjusted EBITDA of $51.6 million, setting the stage for the Q3 results and the forthcoming acquisition.

The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.